The rise of cybersecurity threats gives biopharma and other industries a new and unfamiliar problem that they are ill-equipped to handle alone. In response, an increasing number of biopharma companies are outsourcing cybersecurity activities, a strategy that has been vindicated by a new report.
Speaking at an investor day late last week, Novartis chief financial officer Harry Kirsch outlined how the company plans to generate "substantial savings" by working with external data management vendors.
While it's not a needed blockbuster approval, Merck's clinical crew has claimed a modest victory on the off-shoring front with a reduction in data-management expenses.
As software providers know well, AstraZeneca has been one of the most prolific users of information technology in the pharma world. So the drugmaker's IT preferences and activities garner attention, including the messy court showdown between the company and IBM.
An influential group of industry critics has reshuffled its listing of Big Pharma companies, lauding some big players like Johnson & Johnson for improving access to therapies and promoting R&D on neglected diseases while handing out worsening grades to many others. And the entire industry earned a black eye for outsourcing more of their drug development efforts without safeguards to make sure the work being done for them is safe and ethical.
Drawn by a growing drug market and a massive patient population, the pharmas have been creating their own research organizations in the country. And in the process a multibillion-dollar market in partnerships with R&D outsourcers, local drug developers and academic groups has flowered--with the promise of billions more to come.
Under its private equity masters at Bain Capital and TPG Capital, Quintiles has been rapidly beefing up its clinical-to-commercial outsourcing operations around the globe. Now Bloomberg reports that the makeover may lead to one very big cash-out as Quintiles execs ponder filing an IPO.
Access to patients trumps cost among pharma outsourcers shopping for CROs, according to a new poll from ISR Reports.
Charles River increased global IT spending by 20% in the second quarter as it continued investing to win strategic deals. And the policy is paying dividends, with execs calling IT a driver of market share gains in the quarter.
Valued at $49.4 million in terms of revenue in 2010 (a small but growing figure), the Argentine clinical trial market is forecast to grow at a compound annual growth rate of 9% between 2010 and 2015.